Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients' prognosis and pharmacotherapy : MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

Affiliations

• ¹ Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
• ² CIBERehd. Instituto de Salud Carlos III, Madrid, Spain.
• ³ Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
• ⁴ Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. maavila@unav.es.
• ⁵ CIBERehd. Instituto de Salud Carlos III, Madrid, Spain. maavila@unav.es.
• ⁶ Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain. maavila@unav.es.